Nervous in Biological Technology
Navigation Links
Nervous in Biological Technology
Omeros Appoints New Vice President of Clinical Development
... "In addition, we have several preclinical central nervous system and inflammation programs that have the ... company that developed treatments for central nervous system disorders and was acquired by Hoffman-La ... on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product ...UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases
... produce this critical myelin. In the peripheral nervous system, where the problems associated with ... Due to the famous complexity of the nervous system, studying demyelinating neuropathies has ... environments. In the relatively open peripheral nervous system, cells are exposed to blood and other ...... that works at two levels within the central nervous system: one associated with controlling the ... to target these reward centers in the central nervous system. Based on clinical trials completed to ... act on a specific group of neurons in the central nervous system with the goal of achieving appetite ...
... innovative treatments for diseases of the central nervous system (CNS), today announced issuance of a new ... so their activity is restricted to the peripheral nervous system, with minimal or no central nervous system activity. CNS side effects associated ...
... delivering breakthrough therapies in central nervous system (CNS) diseases, today launched Axona(TM) ... focused on developing new therapies for central nervous system disorders, we're very excited about ... product breakthroughs in treating central nervous system disorders. Accera's novel therapeutic ...
... is a growing understanding of how the central nervous system regulates appetite and metabolism as well ... to target these reward centers in the central nervous system. Based on clinical trials completed ... act on a specific group of neurons in the central nervous system with the goal of achieving appetite ...
Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target
... disease, a degenerative disorder of the central nervous system, often impairs motor skills, speech and ... on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product ... programs targeting inflammation and central nervous system disorders. For more information on Omeros, ...... on the treatment of obesity and other central nervous system-related disorders, today announced the ... obesity programs by extending into other central nervous system disorders," said Gary Tollefson, M.D., ... on the treatment of obesity and other central nervous system-related disorders. The Company's lead ...
... on the treatment of obesity and other central nervous system-related disorders, today announced its ... product candidates for the treatment of central nervous system disorders, including obesity. The ... act on a specific group of neurons in the central nervous system with the goal of achieving appetite ...
... on the treatment of obesity and other central nervous system-related disorders, today announced that ... on the treatment of obesity and other central nervous system-related disorders, including obesity. The ... act on a specific group of neurons in the central nervous system with the goal of achieving appetite ...
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
... company focused on the treatment of central nervous system disorders, including obesity, today ... product candidates for the treatment of central nervous system disorders, including obesity. The ... act on a specific group of neurons in the central nervous system with the goal of achieving appetite ...Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
... designed to accelerate recovery from central nervous system disorders, announced today that ... injury, traumatic brain injury and other central nervous system disorders. The NESS H200 Hand ... that aid individuals in the recovery from central nervous system disorders such as stroke, multiple ...ORIMtec Releases Industry's First Intraoperative Monitoring Reference Guide for Neurotechnologists
... monitor to detect impending damage to the nervous system and alert the operating surgeon to reduce the risk of injury to the central and peripheral nervous system during cranial and spinal surgeries. It is ... service that reduces the risk of injury to the nervous system during head, neck and back surgeries. ...MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
... largest pharmaceutical companies with central nervous system drug candidates, and has administered more ... of enhancing precision and reliability in central nervous system trials head-on. This capital infusion will ... failure rates, and get more effective central nervous system (CNS) drugs to market sooner. MedAvante ...Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
... 2310 - Hunter syndrome with significant central nervous system symptoms - Following the acceptance by ... Hunter syndrome patients with significant central nervous system symptoms - "Hunter CNS"), the Company ... on providing prescription drugs for central nervous system (CNS) disorders. The disposal generated ...Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
... cause life-threatening central nervous system infections (CNSI), and rapid diagnosis ... can also cause serious central nervous system infections such as encephalitis. Without ... are typical in the early stages of a central nervous system infection. "We believe that in the ...Anavex advances drug candidate for treatment of Alzheimer's disease
... protection to any part of the body's nervous system, through the prevention of oxidative ... the nerve cells that make up the central nervous system, from degeneration or death. Testing was ... family of proteins, present mainly in the Central nervous System (CNS) but also in various peripheral ...Scientists create colorful 'brainbow' images of the nervous system
... at Harvard University are imaging the brain and nervous system as never before, rendering their cells in ... in charting the circuitry of the brain and nervous system. "In the same way that a television ... can use to tease out the wiring diagram of the nervous system; Brainbow should help us much better map ...Treatment blocks pain without disrupting other functions
... This can cause numbness, paralysis and other nervous system disturbances. "The Holy Grail in pain ... coordination, or other vital functions of the nervous system. This finding shows that a specific ... NIH, that shows how electrical signaling in the nervous system results from expression of dozens of ...Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
... and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ... and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit ...Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
... of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune ... Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. The company's proprietary ...... Effects of Tolterodine, Trospium chloride, and Oxybutynin on the Central nervous System. J Clin Pharm 41: 636-644 (2001) [10] Diefenbach K, Arold G, ... Effects of Tolterodine, Trospium chloride, and Oxybutynin on the Central nervous System. J Clin Pharm 41: 636-644 (2001) [21] Diefenbach K, Arold G, ...
... and commercialization of products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. Cephalon currently ... Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. The company's proprietary ...
... and commercialization of products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. Cephalon currently ... Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. The company's proprietary ...
Vanda Pharmaceuticals Reports First Quarter 2009 Results
... and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for ... and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit ...Accera, Inc. to Present at Upcoming Investor Conferences
... Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) disorders, today announced that the company will be ... company, discovers and develops product breakthroughs in treating central nervous system disorders. Accera's novel therapeutic approaches positively impact ...Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors
... Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today that Thomas Werner, Ph.D. has been ... company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients ...Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin'
... of XYZAL(R). Concurrent use of XYZAL(R) with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions ... of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 12,000 people in ...QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
... on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today the initiation of a comparative ... and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on ...Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference
... Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today it is a SILVER level sponsor of the ... company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients ...Cephalon's New Product Launches Pace Record 2008 Sales
... of the company's earnings guidance range of $5.20 to $5.30. Central nervous system (CNS) franchise sales for 2008 increased 15 percent compared to ... of many unique products in three core therapeutic areas: central nervous system, pain, and oncology. A member of the Fortune 1000 and the S&P ...Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
... and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for ... and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit ...Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
... of many unique products in three core therapeutic areas: central nervous system, pain, and oncology. A member of the Fortune 1000 and the S&P ... Europe markets more than 30 products in four therapeutic areas: central nervous system, pain, primary care and oncology. The company's proprietary ...Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
... against many different kinds of normal human brain cells for new Central nervous System (CNS) drugs, and stem cell-mediated protein delivery for neurologic ... mature, physiologically relevant human neurons and glia. Major Central nervous System diseases targeted by the Company with research programs currently ...QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
... on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced today initiation of a comparative study ... and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on ...Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
... products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived ... pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web ...BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
... that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today the appointment of David E. ... to identify and reposition compounds for the treatment of central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous ...Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
... company focused on the treatment of obesity and other central nervous system-related disorders, today announced unaudited financial results for ... company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product ...Cephalon Reports Another Strong Quarter
... in 2007, exceeding the company's guidance of $1.25 to $1.35. Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 ... of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, ...CeNeRx BioPharma Completes $15 Million Series B Financing
... and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $15 million Series B ... and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of ...Other ContentslosslosslosslosslosslosslosslosslosslossgaingaingaingaingaingaingaingaingainwestwestwestmanagementmanagementmanagementmanagementmanagementmanagementmanagementmanagementmanagementweightweightweightweightweightweightweightweightweightweightwheezingwheezingwhiteheadwhiplashwhiplashOther TagsKitKitKitKitColorimetricGSTGSTGSTCruztransferasetransferaseCaymanCorporationCorporationInstrumentsInstrumentsAbcamOther Tagsunmarried 2she 2she 3she 4she 5she 6she 7she 8she 9she 10botulinum 2rats 2rats 3rats 4rats 5rats 6rats 7rats 8tracks 2parasites 2parasites 3parasites 4parasites 5microscopic 2microscopic 3microscopic 4microscopic 5microscopic 6microscopic 7offers 2offers 3offers 4offers 5offers 6offers 7offers 8offers 9offers 10five 2five 3five 4five 5five 6five 7five 8five 9five 10
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
Breaking Biology News(10 mins):Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2Taking dex can improve high altitude exercise capacity in certain climbers 54225 1Taking dex can improve high altitude exercise capacity in certain climbers 54225 2Taking dex can improve high altitude exercise capacity in certain climbers 54225 3Health Insurance Provider Sites Attract Fewer U S Visitors as Unemployment Increases 54224 1Health Insurance Provider Sites Attract Fewer U S Visitors as Unemployment Increases 54224 2Health Insurance Provider Sites Attract Fewer U S Visitors as Unemployment Increases 54224 3World Stem Cell Summit to Be Held in Baltimore 13504 1World Stem Cell Summit to Be Held in Baltimore 13504 2(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2[0] Free Health Clinic Event Is Not Just for the Sick[0] Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist[0] Natural Products Association Issues Statement on DEA's Steroid Classification Action[0] Muscle cell infusion shown to strengthen sphincters in animals in Stanford study[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |